Morningstar

Pfizer Inc PFE

Morningstar Rating
Unlock
Stock XNYS Rating as of
$24.94 +0.19 (0.77%)
View Full Chart
As of Delayed Price Closed

Company Report

View Archive

Pfizer's Diversified Portfolio Supports a Narrow Moat Despite an Upcoming Patent Cliff

Karen Andersen

Pfizer's foundation remains solid, based on steady cash flows generated from a basket of diverse drugs. The company's large size confers significant competitive advantages in developing new drugs. This heft, combined with a broad portfolio of patent-protected drugs, has helped Pfizer build an economic moat around its business. In addition, Pfizer's 2020 divestment of its off-patent division Upjohn to create a new company (Viatris) in combination with Mylan, as well as its consumer business spinoff (Haleon) in 2022, should help focus the remaining innovative business.

Read Full Report

Price vs Fair Value

View History
PFE is trading at a LOCK|cr##YJ? premium.
Price
$25.05
Fair Value
C!
Uncertainty
LOCK|qW?r
1-Star Price
LOCK|.q
5-Star Price
LOCK|.f
Economic Moat
LOCK|WmY<
Capital Allocation
LOCK|fpsV&zK

Bulls Say, Bears Say

Bulls

Pfizer's portfolio contains several blockbusters, including differentiated cardiovascular drug Vyndaqel and oncology drug Padcev.

Bears

Aggressive cost-cutting in research and development could hurt Pfizer's long-term prospects, given the importance of continued investment in innovation.

Show More

News

View All

Articles & Videos

Trading Information

Previous Close Price
$24.75
Day Range
$24.65–25.01
52-Week Range
$23.11–28.75
Bid/Ask
$24.89 / $24.91
Shares Outstanding
5.70B
Market Cap
$142.14B
Volume/Avg
27M / 41M

Key Statistics

Price/Earnings (Normalized)
8.15
Price/Sales
2.25
Dividend Yield (Trailing)
6.90%
Dividend Yield (Forward)
6.90%
Total Yield
6.90%

Company Profile

Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13 and cardiology drugs Vyndaqel and Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.
Sector
Healthcare
Industry
Drug Manufacturers - General
Stock Style Box
Large Value
Total Number of Employees
75,000
Website
https://www.pfizer.com

Competitors

Valuation

View More
Metric
PFE
LLY
GSK
Price/Earnings (Normalized)
 8.1540.0810.92
Price/Book Value
 1.5833.774.34
Price/Sales
 2.2514.662.37
Price/Cash Flow
 8.3339.418.86
Price/Earnings
PFE
LLY
GSK

Financial Strength

Metric
PFE
LLY
GSK
Quick Ratio
 0.850.720.51
Current Ratio
 1.251.500.79
Interest Coverage
 3.73—11.71
Quick Ratio
PFE
LLY
GSK

Profitability

Metric
PFE
LLY
GSK
Return on Assets (Normalized)
 8.40%24.73%11.47%
Return on Equity (Normalized)
 19.47%114.33%44.00%
Return on Invested Capital (Normalized)
 12.80%40.96%22.62%
Return on Assets
PFE
LLY
GSK

Drug Manufacturers - General Industry Comparables

Screen With Investor
1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Eli Lilly and Co
LLY
LOCK|$NSwV$sLOCK|L>$1T
 Johnson & Johnson
JNJ
LOCK|>RN&%@ZLOCK|nS>$609B
 AbbVie Inc
ABBV
LOCK|?yKrxcLOCK|^<$450B
 Roche Holding AG ADR
RHHBY
LOCK|<LTNY^&LOCK|fg$330B
 Merck & Co Inc
MRK
LOCK|XqJzq%LOCK|<&$315B
 Novartis AG ADR
NVS
LOCK|V&kPH!TLOCK|MW$295B
 AstraZeneca PLC
AZN
LOCK|@!R><>Z@LOCK|<h$263B
 Novo Nordisk AS ADR
NVO
LOCK|!rD#nrLOCK|&Gx$223B
 Amgen Inc
AMGN
LOCK|Y#N<!KMLOCK|?H$198B
 Gilead Sciences Inc
GILD
LOCK|&P&GxxfLOCK|d&T$167B

Sponsor Center